

SSF John Jane Annual Visiting Surgeon Lectureship – Disclosure Summary Thursday, August 1, 2024

The following planners and speakers, in the past 24 months, have/had a financial relationship with an ineligible company: (S=Speaker; P=Planner)

Jens R. Chapman, M.D (P): Advisor: Globus Medical; Fellowship Grant Support: Globus Medical; Consultant: Xtant

Rod J. Oskouian, Jr. M.D. (P): Consultant: Alphatec Spine, Globus Medical, SeaSpine, Stryker, Spineart, Medtronic, DePuy Synthes, Blue Ocean Spine; Royalties: Stryker, Globus Medical; Fellowship Grant Support: Globus Medical

All the relevant financial relationships listed for these individuals have been mitigated.

The following planners and speakers, in the past 24 months, have/had no financial relationship with an ineligible company:

Nelson Oyesiku, M.D. (S); **Gerrit Lewik, M.D.** (P); **Julius Gerstmeyer, M.D.** (P); **Linda Sahlin, B.A.** (P)

Purpose: The information provided addresses several requirements of the Accreditation Council for Continuing Medical Education (ACCME) to help **ensure independence** in CME activities. Everyone in a position to control the content of a CME activity must disclose **ALL** financial relationships with an ineligible company to the CME provider. This information must be disclosed to participants prior to the beginning of the activity. Also, CME providers must mitigate current conflicts of interest prior to the educational activity.

Definitions: “Financial relationships” are those whose relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit.

The ACME defines **ineligible companies** as those whose primary business is producing marketing, selling, reselling, or distributing healthcare products used by or on patients.

Among the exemptions to this definition are government organizations non healthcare-related companies and nonprofit organizations that do not advocate for ineligible companies. Circumstances create a “**conflict of interest**” when an individual has an opportunity to affect the CME contact about products or services of an ineligible company with which they have a financial relationship.

ACCME focuses on financial relationships with ineligible companies in the 24-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

For CME Mitigation Purposes the ACCME defines “**relevant financial relationships**” as financial relationships in any amount occurring within the past 24 months that create a conflict of interest.

CME Activity Planning Committee Members: if a conflict of interest exists, the Planning Committee member must withdraw from the planning committee unless the conflict can be mitigated. Mitigation may be made by one of the following methods: (1) Peer review of CME content will be conducted at another oversight level to assure balance; (2) Change in focus of course so the activity does not include information related to products or services about which the Planning Committee has a conflict; (3) Severing relationship(s) between the member and any related ineligible company; (4) Others to be determined by the SSF CME committee.

CME Activity Planners: When a conflict of interest exists, the planning committee must address the conflict by one of the following methods: (1) Review content to be presented by speaker in advance to ensure content balance; (2) Change topic so the presentation is not related to products or services where a conflict exists; (3) Select a different presenter without may related relationship with an ineligible company; (4) Include presentations by other faculty to provide an overall balance to the content of the course; (5) Limit or specify the sources for recommendations that the presenter can use.

Each speaker is required to give a balanced, evidenced-based presentation based on published research. No conclusions or recommendations without external validation may be made by a speaker with a conflict of interest.

SSF John Jane Annual Visiting Surgeon Lectureship

Thursday, August 1, 2024

Featured Speaker:

Nelson Oyesiku, M.D.

Professor and Chair, Department of Neurological Surgery and Professor of Medicine (Endocrinology) at the University of North Carolina, Chapel Hill

Topic:

Current Management of Cushings Disease

Agenda

- | | |
|-----------|--------------------------|
| 7 a.m. | Welcome and Introduction |
| 7:01 a.m. | Featured Speaker |
| 7:50 a.m. | Q & A |
| 8 a.m. | Adjourn |

Series Objectives

By attending this course, the participant will provide better patient care through an increased ability to:

- Identify and define the emerging technologies used in the treatment of neurosurgical disorders
- Discuss new treatment modalities used in the treatment of neurosurgical disorders
- Integrate new diagnostic tools used in the treatment of complex neurosurgical disorders
- Apply new surgical procedures for the treatment of brain and spine disorders

Series Description

The Neurosurgery Grand Rounds Series is a recurring educational conference series held for health care providers who treat neurosurgical disorders. Experts in the field will provide didactic lectures on current and emerging interventions for cranial and spinal neurosurgical conditions, focusing on identification, treatment, and improvement in patient care.

Acknowledgments

None

Planning Committee

Rod Oskouian, Jr., M.D., *Chairman*
Jens R. Chapman, M.D.
Gerrit Lewik, M.D.
Julius Gerstmeyer, M.D.
Linda Sahlin, B.A.

Accreditation

Seattle Science Foundation (SSF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

SSF designates this live activity for a maximum of 12 *AMA PRA Category 1 Credit(s)™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each session is designated for 1 *AMA PRA Category 1 Credit™*.

Evaluation and Outcomes

At the end of each session, attendees will complete a survey to evaluate the conference and describe ways in which the material presented will impact their practice.